Rivera et al., 2022 - Google Patents
SARS-CoV-2/COVID-19 and its relationship with NOD2 and ubiquitinationRivera et al., 2022
View PDF- Document ID
- 1923239974775201597
- Author
- Rivera E
- Patnaik A
- Salvemini J
- Jain S
- Lee K
- Lozeau D
- Yao Q
- Publication year
- Publication venue
- Clinical Immunology
External Links
Snippet
COVID-19 infection activates the immune system to cause autoimmune and autoinflammatory diseases. We provide a comprehensive review of the relationship between SARS-CoV-2, NOD2 and ubiquitination. COVID-19 infection partly results from host inborn …
- 101700040223 NOD2 0 title abstract description 96
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rivera et al. | SARS-CoV-2/COVID-19 and its relationship with NOD2 and ubiquitination | |
| Xia et al. | IL4 (interleukin 4) induces autophagy in B cells leading to exacerbated asthma | |
| O’Brien et al. | Obesity reduces mTORC1 activity in mucosal-associated invariant T cells, driving defective metabolic and functional responses | |
| Law et al. | Interferon subverts an AHR–JUN axis to promote CXCL13+ T cells in lupus | |
| Cai et al. | BCAT2 shapes a noninflamed tumor microenvironment and induces resistance to anti‐PD‐1/PD‐L1 immunotherapy by negatively regulating proinflammatory chemokines and anticancer immunity | |
| Saigusa et al. | Multifaceted contribution of the TLR4-activated IRF5 transcription factor in systemic sclerosis | |
| Werner et al. | Identification of pancreatic glycoprotein 2 as an endogenous immunomodulator of innate and adaptive immune responses | |
| Dong et al. | Aberrant expression of circulating Th17, Th1 and Tc1 cells in patients with active and inactive ulcerative colitis | |
| Gong et al. | Cancer-specific type-I interferon receptor signaling promotes cancer stemness and effector CD8+ T-cell exhaustion | |
| Qian et al. | ZEB1 promotes pathogenic Th1 and Th17 cell differentiation in multiple sclerosis | |
| Ruan et al. | Ubiquitin-modifying enzymes as regulators of colitis | |
| Chen et al. | Interleukin‐33 alleviates psoriatic inflammation by suppressing the T helper type 17 immune response | |
| Xu et al. | Nuclear carbonic anhydrase 6B associates with PRMT5 to epigenetically promote IL-12 expression in innate response | |
| Eastman et al. | Epigenetic stabilization of DC and DC precursor classical activation by TNFα contributes to protective T cell polarization | |
| Shahbaz et al. | Differential transcriptional and functional properties of regulatory T cells in HIV‐infected individuals on antiretroviral therapy and long‐term non‐progressors | |
| Agrawal et al. | Sex-related differences in innate and adaptive immune responses to SARS-CoV-2 | |
| Coulibaly et al. | STAT3 governs the HIF-1α response in IL-15 primed human NK cells | |
| Keenan et al. | Polycomb repressive complex 2 is a critical mediator of allergic inflammation | |
| Miller et al. | Frontline Science: RIP2 promotes house dust mite–induced allergic airway inflammation | |
| Raposo et al. | System A amino acid transporters regulate glutamine uptake and attenuate antibody‐mediated arthritis | |
| Wan et al. | MicroRNA 182 promotes T helper 1 cell by repressing hypoxia induced factor 1 alpha in experimental autoimmune encephalomyelitis | |
| Lenehan et al. | Type 2 immunity is maintained during cancer-associated adipose tissue wasting | |
| Liu et al. | Inhibition of Piezo1 ameliorates intestinal inflammation and limits the activation of group 3 innate lymphoid cells in experimental colitis | |
| Chia et al. | Respiratory viral infections awaken metastatic breast cancer cells in lungs | |
| Li et al. | Interleukin‐27 as a negative regulator of human neutrophil function |